Annals of oncology : official journal of the European Society for Medical Oncology
-
Clinical Trial
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
This trial was performed to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetic profile of irinotecan (CPT-11) when administered on a once-every-2-week schedule. ⋯ When administered every two weeks, the recommended phase II starting dose of CPT-11 is 250 mg/m2 when given alone and 300 mg/m2 when supported by G-CSF. This every-two-week regimen offers a tolerable and active alternative to weekly or every-three-week single-agent CPT-11 therapy.